EU Safety Gate (RAPEX) · France · 2024-01-19 · Serious risk
🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Reported risk: Le produit est hautement inflammable et contient du salicylate de benzyle (valeur mesurée 0,28 % en poids). Le salicylate de benzyle peut provoquer une irritation et des réactions allergiques. De plus, le flacon ne comporte pas d'avertissement tactile de danger. L'étiquetage sur l'emballage (carton et flacon) ne comporte pas les informations de danger et d'avertissement appropriées. Le produit n'est pas conforme au règlement sur la classification, l'étiquetage et l'emballage des substances et des mélanges (CLP).
Action taken by the authority
Type of economic operator taking notified measure
Retailer
Category of measure
Recall of the product from end users
Date of entry into force
14/11/2023
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): Spray d'intérieur
Risk Description (original English): The product is highly flammable and contains benzyl salicylate (measured value 0.28% by weight). Benzyl salicylate can cause irritation and allergy reactions. Moreover, he bottle does not have a tactile warning of danger. The labelling on the packaging (carton and bottle) does not include the appropriate hazard and warning information.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.